Subcutaneous Infliximab After A Previous Intravenous Dose Optimization

PHASE4RecruitingINTERVENTIONAL
Enrollment

275

Participants

Timeline

Start Date

April 9, 2024

Primary Completion Date

May 31, 2026

Study Completion Date

November 30, 2026

Conditions
Inflammatory Bowel DiseasesCrohn DiseaseUlcerative Colitis
Interventions
DRUG

Infliximab

Weekly administration of subcutaneous infliximab.

DRUG

Infliximab

Bi-weekly administration of subcutaneous infliximab.

DRUG

Infliximab

Optimized dosing schedule of intravenous infliximab.

Trial Locations (15)

Unknown

RECRUITING

AZ Maria Middelares, Ghent

RECRUITING

AZ Oostende, Ostend

RECRUITING

Universitair ziekenhuis Antwerpen, Antwerp

RECRUITING

Imeldaziekenhuis, Bonheiden

NOT_YET_RECRUITING

AZ Sint-Jan Brugge, Bruges

RECRUITING

Erasme, Brussels

RECRUITING

Ziekenhuis Oost-Limburg, Genk

RECRUITING

AZ Sint-Lucas Gent, Ghent

RECRUITING

Universitair ziekenhuis Gent, Ghent

RECRUITING

Universitair ziekenhuis Leuven, Leuven

RECRUITING

Heilig Hart ziekenhuis Lier, Lier

RECRUITING

CHU Liège - Sart Tilman, Liège

RECRUITING

VITAZ, Sint-Niklaas

RECRUITING

AZ Vesalius, Tongeren

RECRUITING

CHwapi, Tournai

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Celltrion

INDUSTRY

lead

Belgian Inflammatory Bowel Disease Research and Development (BIRD) VZW

OTHER